Tirzepatide achieved superior A1C and body weight reductions across all three doses compared to injectable semaglutide in adults with type 2 diabetes
- Thursday, March 4, 2021, 7:04
- Finance
- Add a comment
INDIANAPOLIS, March 4, 2021 /PRNewswire/ — Tirzepatide led to superior A1C and body weight reductions from baseline across all three doses compared to injectable semaglutide 1 mg in adults with type 2 diabetes in Eli Lilly and Company’s (NYSE: LLY) 40-week SURPASS-2 clinical trial. In…
About the Author
adminasapcorp has written 41302 stories on this site.